Table 3 Patients’ characteristics

Age, years

43

40

44

0.202

median (IQR)

(28.0–61.0)

(26.0–54.0)

(33.0–66.0)

Sex, n (%)

0.322

 Male

61 (64.9)

18 (75.0)

43 (61.4)

 Female

33 (35.1)

6 (25.0)

27 (38.6)

Weight, kg

69

70.8

67.2

0.276

median (IQR)

(55.3–77.6)

(60.9–79.1)

(54.6–77.3)

APACHE-II score

15

14

15

0.546

median (IQR)

(11.0–21.0)

(11.0–20.0)

(12.0–21.0)

SOFA score

3

3

3

0.672

median (IQR)

(1.0–4.0)

(2.0–3.0)

(1.0–4.0)

ISS

22

18

24.5

0.062

median (IQR)

(13.0–34.0)

(9.0–34.0)

(14.5–34.8)

Major injury site, n (%)

0.485

Head and neck

21 (22.3)

7 (29.2)

14 (20.0)

Chest

21 (22.3)

6 (25.0)

15 (21.4)

Abdomen

2 (2.1)

1 (4.2)

1 (1.4)

Limb and pelvis

50 (53.2)

10 (41.7)

40 (57.1)

Complicated injuries, n (%)

47 (50.0)

10 (41.7)

37 (52.9)

0.478

Blood transfusion, n (%)

2 (2.1)

0 (0.0)

2 (2.9)

1.000

Mechanical prophylaxis, n (%)

0.354

IPC

43 (45.7)

13 (54.2)

30 (42.9)

Compression stockings

51 (54.3)

11 (45.8)

40 (57.1)

Prophylactic anticoagulation, n (%)

0.249

Fondaparinux

55 (58.5)

12 (50.0)

43 (61.4)

Heparin calcium

30 (31.9)

11 (45.8)

19 (27.1)

Edoxaban

9 (9.6)

1 (4.2)

8 (11.4)

^aStarted within 48 h, n (%)

17 (18.1)

5 (20.8)

12 (17.1)

0.760

Start day of initial prophylactic anticoagulation from admission

8

4.5

9

0.024

median (IQR)

(3.3–14.0)

(3.0–9.0)

(4.3–15.8)

Laboratory data on pre-prophylactic anticoagulation

median (IQR)

 Hb (g/dL)

9.5

10.2

9.4

0.052

(8.6–11.4)

(8.8–12.9)

(8.6–10.8)

 Plt (10^4 /μL)

24.2

22.1

25.9

0.273

(17.8–34.6)

(18.3–26.6)

(17.6–36.4)

 T-Bil (mg/dL)

0.8

0.8

0.8

0.771

(0.6–1.2)

(0.6–1.3)

(0.6–1.2)

 AST (IU/L)

36

33

37

0.585

(26.3–68.8)

(26.8–60.0)

(25.5–72.5)

 ALT (IU/L)

34.5

30.5

35

0.493

(22.0–74.8)

(22.5–57.0)

(22.0–84.3)

 CLcr (mL/min)

143.4

145.9

139.5

0.677

(117.0–164.5)

(123.4–172.5)

(108.9–163.4)